30 studies found for:    "Li Fraumeni syndrome"
Show Display Options
Rank Status Study
21 Active, not recruiting To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Condition: Small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Biological: Drug: Ad.p53-DC vaccines;   Drug: All -trans Retinoic Acid (ATRA)
22 Completed Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Conditions: Lip and Oral Cavity Cancer;   Oropharyngeal Cancer;   Stage 0 Lip and Oral Cavity Cancer;   Stage 0 Oropharyngeal Cancer;   Tongue Cancer
Interventions: Biological: Ad5CMV-p53 gene;   Other: laboratory biomarker analysis
23 Completed
Has Results
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Condition: Progressive Metastatic Malignancies
Intervention: Biological: ALT-801
24 Active, not recruiting Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Cisplatin;   Biological: ALT-801
25 Recruiting Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Conditions: Familial Ovarian Cancer;   Familial Breast Cancer;   BRCA1-associate Malignancies;   BRCA2-associated Malignancies
Intervention:
26 Recruiting A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Condition: Non-muscle Invasive Bladder Cancer
Interventions: Biological: ALT-801;   Drug: Gemcitabine
27 Recruiting A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Conditions: Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801
28 Active, not recruiting A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Intervention: Biological: ALT-801
29 Withdrawn Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Condition: Acute Myelogenous Leukemia
Interventions: Drug: cenersen;   Drug: placebo;   Drug: idarubicin and cytarabine (chemotherapy)
30 Completed P53 in Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page
Indicates status has not been verified in more than two years